Lupin Ltd

Lupin Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lupin Ltd

₹ 2,265 -1.01%
26 May 12:26 p.m.
lupin.com BSE: 500257 NSE: LUPIN
About

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Key Points

Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]

Website BSE NSE
  • Market Cap ₹ 1,03,555 Cr.
  • Current Price ₹ 2,265
  • High / Low ₹ 2,494 / 1,837
  • Stock P/E 18.0
  • Book Value ₹ 491
  • Dividend Yield 0.52 %
  • ROCE 30.3 %
  • ROE 29.1 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has delivered good profit growth of 37.4% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 17.1%

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 100 BSE 200 BSE Dollex 200

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
4,430 4,814 5,039 5,197 4,961 5,600 5,673 5,768 5,667 6,268 7,048 7,168 7,475
3,852 3,958 4,121 4,159 3,964 4,359 4,332 4,412 4,346 4,541 4,706 4,906 4,989
Operating Profit 578 856 918 1,038 997 1,241 1,340 1,356 1,321 1,727 2,341 2,262 2,486
OPM % 13% 18% 18% 20% 20% 22% 24% 24% 23% 28% 33% 32% 33%
37 23 40 29 29 68 42 54 57 79 90 -312 9
Interest 93 86 81 74 71 68 71 67 89 92 108 115 120
Depreciation 264 235 248 257 457 248 257 271 393 299 317 313 447
Profit before tax 258 559 630 736 498 993 1,055 1,071 896 1,416 2,007 1,522 1,928
Tax % 6% 19% 21% 16% 26% 19% 19% 20% 13% 14% 26% 22% 24%
242 453 495 619 368 806 859 859 782 1,221 1,485 1,181 1,469
EPS in Rs 5.19 9.94 10.76 13.47 7.89 17.58 18.69 18.74 16.92 26.69 32.36 25.73 31.94
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
12,770 14,256 17,367 15,797 14,665 15,375 15,163 16,405 16,642 20,011 22,708 27,958
9,146 10,564 12,865 12,649 12,104 13,020 12,596 16,187 14,921 16,211 17,430 19,142
Operating Profit 3,624 3,691 4,502 3,148 2,561 2,355 2,567 219 1,721 3,800 5,278 8,816
OPM % 28% 26% 26% 20% 17% 15% 17% 1% 10% 19% 23% 32%
235 184 106 -1,310 91 -134 138 210 151 131 202 -133
Interest 10 59 153 204 302 363 141 143 274 312 295 434
Depreciation 435 487 912 1,086 846 970 887 1,659 881 1,197 1,169 1,376
Profit before tax 3,415 3,329 3,543 547 1,503 887 1,676 -1,372 716 2,422 4,015 6,873
Tax % 28% 32% 28% 53% 59% 130% 27% 10% 38% 20% 18% 22%
2,444 2,270 2,565 258 615 -270 1,228 -1,528 448 1,936 3,306 5,355
EPS in Rs 53.47 50.17 56.63 5.56 13.40 -5.95 26.81 -33.62 9.45 42.01 71.88 116.65
Dividend Payout % 14% 15% 13% 90% 37% -101% 24% -12% 42% 19% 17% 15%
Compounded Sales Growth
10 Years: 7%
5 Years: 13%
3 Years: 19%
TTM: 23%
Compounded Profit Growth
10 Years: 10%
5 Years: 37%
3 Years: 141%
TTM: 78%
Stock Price CAGR
10 Years: 4%
5 Years: 14%
3 Years: 43%
1 Year: 15%
Return on Equity
10 Years: 10%
5 Years: 13%
3 Years: 22%
Last Year: 29%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 90 90 90 90 90 91 91 91 91 91 91 91
Reserves 8,784 11,073 13,407 13,487 13,652 12,446 13,712 12,062 12,374 14,199 17,112 22,357
537 7,178 7,966 7,143 8,496 6,305 5,129 4,158 4,542 2,922 5,448 6,616
3,642 3,957 4,749 5,300 5,423 5,968 4,498 5,340 5,794 6,539 6,327 9,300
Total Liabilities 13,054 22,298 26,212 26,020 27,661 24,810 23,430 21,651 22,800 23,751 28,978 38,365
4,368 8,717 11,033 10,362 11,087 7,938 7,881 7,382 8,355 8,878 9,719 11,315
CWIP 576 2,702 2,133 2,598 1,640 940 1,066 1,146 1,238 773 517 695
Investments 1,658 16 2,136 262 2,295 2,374 2,455 900 517 1,075 1,146 3,670
6,451 10,862 10,910 12,798 12,639 13,557 12,028 12,224 12,690 13,026 17,596 22,685
Total Assets 13,054 22,298 26,212 26,020 27,661 24,810 23,430 21,651 22,800 23,751 28,978 38,365

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,733 -382 4,114 1,751 1,666 1,469 1,822 367 1,897 3,648 3,000 7,334
-1,034 -6,769 -2,527 470 -3,282 1,107 -1,240 1,292 -1,287 -1,712 -4,172 -3,865
-197 5,836 433 -1,492 744 -891 -1,885 -1,572 -337 -2,184 1,732 -846
Net Cash Flow 1,502 -1,315 2,019 729 -872 1,685 -1,303 87 273 -248 560 2,624
Free Cash Flow 1,865 -6,164 1,513 261 706 798 1,150 -531 436 2,732 1,347 5,527
CFO/OP 101% 21% 117% 73% 102% 84% 98% 146% 124% 105% 74% 98%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 76 116 91 120 128 129 108 95 98 86 88 86
Inventory Days 220 276 266 253 283 232 279 261 242 272 292 303
Days Payable 172 168 189 178 184 162 137 129 136 163 158 208
Cash Conversion Cycle 124 225 167 195 227 199 249 227 204 195 223 181
Working Capital Days 56 102 63 126 115 33 34 45 32 53 58 75
ROCE % 40% 24% 19% 10% 10% 9% 9% -7% 6% 16% 21% 30%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Sales
%

Log in to view insights

Please log in to see hidden values.

Login
ANDA Approvals (Cumulative)
Number
ANDA Filings (Cumulative)
Number
Number of Manufacturing Sites
Number
US FDA ANDA Filings (Annual)
Number
Total Workforce
Number
India Medical Representatives (Sales Force)
Number
US DMF Filings (Cumulative)
Number
US GxF TRx Volume Share
%
India Market Share - Anti-TB
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
47.07% 47.06% 47.04% 47.01% 46.99% 46.96% 46.94% 46.91% 46.90% 46.89% 46.89% 46.85%
13.93% 14.99% 16.11% 18.29% 19.32% 21.50% 22.04% 21.46% 21.25% 20.50% 21.50% 21.70%
29.08% 29.14% 29.72% 27.76% 26.77% 25.10% 24.73% 25.41% 25.55% 26.56% 25.58% 25.32%
0.28% 0.28% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00%
9.62% 8.52% 7.10% 6.93% 6.92% 6.44% 6.27% 6.21% 6.28% 6.06% 6.04% 6.13%
No. of Shareholders 3,22,6782,89,0742,81,5422,80,2482,88,5372,79,2802,81,9882,83,2102,86,6042,80,2562,88,9312,90,411

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls